Drug Approval | April 29, 2026
AbbVie seeks FDA nod for RINVOQ use in severe alopecia areata
After Phase 3 results show major hair regrowth gains
After Phase 3 results show major hair regrowth gains
The company receives approval for blood-based test enabling objective differentiation of schizophrenia and bipolar disorder
With big pharma leaning on external pipelines, the company sees opportunity in de-risked, high-impact assets with clear clinical endpoints
Hyderabad based 400-bed facility brings AI-driven care, advanced imaging, and integrated clinical systems under one roof
Patients, doctors, and caregivers come together to promote awareness, early intervention, and pain-free living
The company has supported the initiative since its inception, contributing to screening efforts in around 120 countries
New home-use glucometer delivers results in under 10 seconds with simplified testing, large memory storage, and user-friendly design
Experts call for integrated, evidence-based approaches to tackle rising dengue, malaria, and chikungunya burden in Indian cities
The lens received U.S. Food and Drug Administration (FDA) market authorization via the De Novo pathway in late 2025
India leads the shift as wellness tourism integrates healthcare, hospitality, and lifestyle
Subscribe To Our Newsletter & Stay Updated
